- Home
- XP vs JAZZ Comparison
XP vs JAZZ Comparison
Compare XP & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XP | JAZZ |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | Cayman Islands | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 10.4B |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | XP | JAZZ |
|---|---|---|
| Price | $20.25 | $187.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $22.67 | ★ $216.93 |
| AVG Volume (30 Days) | ★ 6.4M | 922.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $19.44 | $7.60 |
| Revenue Next Year | $13.81 | $8.34 |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.20 | $95.49 |
| 52 Week High | $23.13 | $198.00 |
Technical Indicators
Market Signals| Indicator | XP | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 66.16 |
| Support Level | $18.05 | $159.78 |
| Resistance Level | $20.37 | N/A |
| Average True Range (ATR) | 1.14 | 5.27 |
| MACD | -0.09 | 2.28 |
| Stochastic Oscillator | 35.46 | 71.25 |
Price Performance
Historical ComparisonAbout XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.